ClinicalTrialsFinder

Refractory Rheumatoid Arthritis (RA) Clinical Trials in Brescia

1 recruitingBrescia, Italy

Showing 1–1 of 1 trials

Recruiting
Phase 2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Systemic Sclerosis (SSc)Refractory Rheumatoid Arthritis (RA)Idiopathic Inflammatory Myopathies (IIMs)
Artiva Biotherapeutics, Inc.90 enrolled26 locationsNCT06991114